Alexander MBA - Pharming Group Chief Officer

PHAR Stock  USD 7.74  0.27  3.61%   

Executive

Alexander MBA is Chief Officer of Pharming Group NV
Age 60
Address Darwinweg 24, Leiden, Netherlands, 2333 CR
Phone31 71 524 7400
Webhttps://www.pharming.com

Pharming Group Management Efficiency

The company has return on total asset (ROA) of (0.0138) % which means that it has lost $0.0138 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0818) %, meaning that it created substantial loss on money invested by shareholders. Pharming Group's management efficiency ratios could be used to measure how well Pharming Group manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/04/2024, Return On Tangible Assets is likely to drop to -0.03. In addition to that, Return On Capital Employed is likely to drop to -0.01. At this time, Pharming Group's Total Assets are relatively stable compared to the past year. As of 12/04/2024, Non Current Assets Total is likely to grow to about 153.8 M, while Other Current Assets are likely to drop slightly above 3.4 M.
Pharming Group NV currently holds 171.54 M in liabilities with Debt to Equity (D/E) ratio of 0.75, which is about average as compared to similar companies. Pharming Group NV has a current ratio of 5.12, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Pharming Group's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Anne DVMMolecular Partners AG
N/A
Sarah FosterMineralys Therapeutics, Common
N/A
Mike CampbellOpthea
N/A
Gopal MBBSRezolute
N/A
Dr MBAVerrica Pharmaceuticals
48
Dr MBAAcrivon Therapeutics, Common
N/A
Jessica IbbitsonMineralys Therapeutics, Common
N/A
Jennifer JohanssonLarimar Therapeutics
N/A
Christopher HayesVerrica Pharmaceuticals
60
Terry EvansFennec Pharmaceuticals
N/A
MD MAOpthea
N/A
Katharine CPAAcrivon Therapeutics, Common
N/A
MD MBAMolecular Partners AG
N/A
Cindy BerejikianMineralys Therapeutics, Common
N/A
MD MBAEliem Therapeutics
50
Peter MBAOpthea
52
Erin OBoyleRezolute
N/A
Jeffrey FellowsMineralys Therapeutics, Common
N/A
PharmD MSOpthea
52
Sarika GulharOpthea
N/A
Anand SundaramOpthea
N/A
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. Pharming Group N.V. is headquartered in Leiden, the Netherlands. Pharming Group operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 277 people. Pharming Group NV (PHAR) is traded on NASDAQ Exchange in USA. It is located in Darwinweg 24, Leiden, Netherlands, 2333 CR and employs 382 people. Pharming Group is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Pharming Group NV Leadership Team

Elected by the shareholders, the Pharming Group's board of directors comprises two types of representatives: Pharming Group inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pharming. The board's role is to monitor Pharming Group's management team and ensure that shareholders' interests are well served. Pharming Group's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pharming Group's outside directors are responsible for providing unbiased perspectives on the board's policies.
Bruno Giannetti, Consultant
MD MBA, CEO President
Susanne Embleton, Investor Manager
Jeroen Wakkerman, Chief Officer
Ruud Outersterp, Chief Officer
Stephen Toor, Chief Americas
Anurag Relan, Chief Officer
MBA MD, CEO Pres
Alexander MBA, Chief Officer
Mireille MSc, Chief Officer
Daniela Hanovana, Chief Officer
MPH MD, Chief Officer

Pharming Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pharming Group a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Additional Tools for Pharming Stock Analysis

When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.